Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers

被引:49
作者
Ho, PC
Ghose, K
Saville, D
Wanwimolruk, S
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
[2] Univ Otago, Dept Pharmacol, Dunedin, New Zealand
关键词
verapamil; calcium antagonist; grapefruit juice;
D O I
10.1007/s002280000189
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To determine the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of S- and R-verapamil (given as racemates) at steady state. Methods: Nine healthy male volunteers followed a randomised cross-over study comprising two treatment periods. Pretreatments of 200 ml orange juice (control) or grapefruit juice twice daily for 5 days and 120 mg verapamil (orally) twice daily for 3 days were given. On the study day, the subjects received the morning dose of verapamil with either orange juice (control) or grapefruit juice. Plasma and urine samples were collected for measurement of S- and R-verapamil and the metabolites S- and R-norverapamil. Blood pressure (BP), heart rate (HR) and PR-interval were monitored. Results: During the grapefruit juice period, the steady-state peak and trough concentrations of S-verapamil were moderately increased (peak 41+/-25 ng ml(-1) versus 26+/-13 ng ml(-1), trough 14+/-7 ng ml(-1) versus 12+/-6 ng ml(-1), P = 0.08). Grapefruit juice significantly increased the area under the plasma concentration-time curve during the 12-h dose interval (AUC(0-12) h) of S-verapamil by 36% (292+/-146 ng h ml(-1) versus 215 +/- 102 ng h mi P = 0.04). Similar results were obtained for peak and trough concentrations of R-verapamil. The AUC(0-12) h of R-verapamil was increased by 28% (1022+/-412 ng h ml(-1) versus 800+/-316 ng h ml(-1), P = 0.04). Elimination half-life and renal clearance of both S- and R-verapamil were not affected. Considerable inter-subject variability in interaction was shown. There were no significant differences in the pharmacodynamic parameters (BP, HR and PR-interval). Conclusions: The present study has demonstrated an interaction between verapamil and grapefruit juice, which is likely due to an inhibition of intestinal metabolism resulting in increased oral bioavailability.
引用
收藏
页码:693 / 698
页数:6
相关论文
共 19 条
[1]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[2]  
Busse D, 1995, N-S ARCH PHARMACOL, V353, P116
[3]   Role of P-glycoprotein-mediated secretion in absorptive drug permeability:: An approach using passive membrane permeability and affinity to P-glycoprotein [J].
Doppenschmitt, S ;
Spahn-Langguth, H ;
Regårdh, CG ;
Langguth, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (10) :1067-1072
[4]   EFFECTS OF D,1-VERAPAMIL ON ATRIOVENTRICULAR-CONDUCTION IN RELATION TO ITS STEREOSELECTIVE 1ST-PASS METABOLISM [J].
ECHIZEN, H ;
VOGELGESANG, B ;
EICHELBAUM, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (01) :71-76
[5]   EFFECTS OF VERAPAMIL ON P-R-INTERVALS IN RELATION TO VERAPAMIL PLASMA-LEVELS FOLLOWING SINGLE IV AND ORAL-ADMINISTRATION AND DURING CHRONIC TREATMENT [J].
EICHELBAUM, M ;
BIRKEL, P ;
GRUBE, E ;
GUTGEMANN, U ;
SOMOGYI, A .
KLINISCHE WOCHENSCHRIFT, 1980, 58 (18) :919-925
[6]  
Fuhr U., 1994, Naunyn-Schmiedeberg's Archives of Pharmacology, V349, pR134
[7]   Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects [J].
Hashimoto, K ;
Shirafuji, T ;
Sekino, H ;
Matsuoka, O ;
Sekino, H ;
Onnagawa, O ;
Okamoto, T ;
Kudo, S ;
Azuma, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (9-10) :753-760
[8]   VERAPAMIL STEREOISOMERISM - ENANTIOMERIC RATIOS IN PLASMA DEPENDENT ON PEAK CONCENTRATIONS, ORAL INPUT RATE, OR BOTH [J].
KARIM, A ;
PIERGIES, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (02) :174-184
[9]   Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue [J].
Kivisto, KT ;
Bookjans, G ;
Fromm, MF ;
Griese, EU ;
Munzel, P ;
Kroemer, HK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) :387-389
[10]  
KROEMER HK, 1992, J PHARMACOL EXP THER, V260, P1052